Table 1.
Characteristics of large-scale studies reporting hepatitis B virus (HBV)-related HCC recurrence rates after anti-viral therapy.
| Author/Year | Patients No. | HCC Tx | F/U(Median) | HCC Recurrence Rate | HR | Ref. | ||
|---|---|---|---|---|---|---|---|---|
| IFN vs. Control | ||||||||
| IFN | Control | IFN | Control | |||||
| Sun 2006 (RCT) |
118 | 118 | Resection | 36.5 months | Median RFS: 31.2 (95% CI: 14.8–47.7) months |
Median RFS: 17.7 (95% CI: 9.2–26.3) months |
p = 0.1425 | [42] |
| Lo 2007 (RCT) |
40 (35 HBV) |
40 (37 HBV) |
Resection | 5 years | 5-year recurrence: 21/40 (52.5%) |
5-year recurrence: 22/40 (55%) | p = 0.311 | [43] |
| Qu 2010 | 101 | 467 | Resection | 53.3 months | year RFS: 86.1% 5-year RFS: 37.5% |
year RFS: 73.9% 5-year RFS: 33.5% |
0.786 (95% CI: 0.597–1.035), p = 0.086 |
[41] |
| Chen 2012 (RCT) |
133 (106 HBV) |
135 (109 HBV) |
Resection | 63.8 months | year RFS: 71.7% 5-year RFS: 41.7% |
year RFS: 75.1% 5-year RFS: 41.3% |
p = 0.766 | [44] |
| Sun 2014 (meta-analysis) |
264 | 267 | Resection | NR | NR | NR | 0.87 (95% CI: 0.70–1.09), p = 0.23 |
[45] |
| NA vs. Control | ||||||||
| NA | Control | NA | Control | |||||
| Chan 2011 | 42 (38: LAM;4: ETV) |
94 | Resection | NR | year RFS: 66.5% 5-year RFS: 51.4% |
year RFS: 48.9% 5-year RFS: 33.8% |
p = 0.05 | [57] |
| Wu 2012 (PSM) |
518 | 4051 | Resection | NA: 2.18 (IQR 1.21–3.69) years Control: 1.57 (IQR:0.77–3.15) years |
6-year recurrence rate: 45.6% (95%CI: 36.5–54.6%) | 6-year recurrence rate: 54.6% (95% CI: 52.5–56.6%) | 0.66 (95% CI: 0.55–0.81), p < 0.001 |
[58] |
| Ke 2013 (PSM) |
141 (LAM) |
337 | Resection | 24 months | year RFS: 73.1% 5-year RFS: 44.5% |
year RFS: 68.8% 5-year RFS: 43.0% |
p = 0.503 | [59] |
| Yin 2013 (RCT) |
81 (LAM) |
82 | Resection | 39.9 (IQR: 27.3–47.8) months | 2-year RFS: 55.6% 4-year RFS: 37.3% |
2-year RFS: 19.5% 4-year RFS: 12.1% |
p < 0.001 | [60] |
| Su 2013 | 62 | 271 | Resection | 45.9 (IQR: 22.4–78.9) months | year RFS: 90.2% 5-year RFS: 57.5% |
year RFS :63.6% 5-year RFS :34.1% |
2.296 (95%CI:1.451–3.632), p < 0.001 | [21] |
| Sun 2014 (meta-analysis) |
1194 (LAM) |
5052 | Resection; RFA |
NR | NR | NR | 0.66 (95% CI: 0.54–0.80), p < 0.0001 |
[61] |
| Huang 2015 (RCT) |
100 (ADV) |
100 | Resection | 60 (range: 4–70) months | year RFS: 85.0% 5-year RFS: 46.1% |
year RFS: 84.0% 5-year RFS: 27.1% |
0.651 (95% CI: 0.451–0.938), p = 0.021 | [62] |
| Chong 2015 | 254 (ETV: 61.0%; LAM: 30.3%; ADV: 5.5%) |
150 | Resection | 52.4 months | year RFS: 74.8% 5-year RFS: 44.7% |
11-year RFS: 61.1% 5-year RFS: 38.1% |
p = 0.166 | [63] |
| Lee 2016 (PSM) |
133 | 266 | RFA | 0.69 (95% CI: 0.50–0.95), p = 0.02 | 2-year recurrence rate: 41.8% (95%CI: 32.9–50.6%) |
2-year recurrence rate: 54.3% (95%CI: 48.0–60.6%) |
[64] | |
| Wong 2016 | 968 | 1230 | Resection; RFA; TACE; |
2.8 (IQR: 1.4–4.9) years | Incidence of recurrence: 10.7 (95% CI: 9.3–12.2) per 100 person-years |
Incidence of recurrence: 16.6 (95% CI: 15.1–18.2) per 100 person-years |
0.63 (95% CI: 0.49–0.80), p < 0.001 | [55] |
| Chen 2017 (meta-analysis) |
2546 | 6463 | Resection | NR | NR | NR | 0.68 (95% CI: 0.51–0.67, p< 0.001) |
[65] |
| NA vs. NA | ||||||||
| NA | NA | NA | NA | |||||
| Cho 2018 (IPDW) |
High-potency NA: 256 |
Low-potency NA: 90 |
Resection; RFA |
53.6 months | High-potency NA Median RFS: 88.2 (IQR: 27.0–103.6) months |
Low-potency NA Median RFS: 25.1 (IQR: 9.7–61.5) months |
0.470 (95% CI: 0.338–0.652), p < 0.001 |
[67] |
| Choi 2020 (PSM) |
ETV: 567 | TDF: 567 | Resection | ETV: 4.4 years TDF: 2.6 years |
ETV 3-year RFS: 64.1% |
TDF 3-year RFS: 73.2% |
0.82 (95% CI: 0.68–0.98), p = 0.03 |
[68] |
Abbreviations: F/U: follow-up duration; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazard ratio; IFN, interferon; RCT, randomized control trial; RFS, recurrence-free survival; CI, confidence interval; NR, not reported; LAM, lamivudine; PSM, propensity score matching; IQR, interquartile range; Ref: reference; RFA, radiofrequency ablation; ADV, adefovir; ETV, entecavir; TACE, transarterial chemoembolization; IPDW, inverse probability-of-treatment weighting; TDF: tenofovir disoproxil fumarate.